Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan(Western University), Wulf O. Böcher(Boehringer Ingelheim (Germany)), Ursula Seidler(Medizinische Hochschule Hannover), Steven J. Padula(Boehringer Ingelheim (Germany)), Denis Franchimont(McGill University Health Centre), Marc Ferrante(Universitair Ziekenhuis Leuven), William J. Sandborn(University of San Diego), Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Julián Panés(Hospital Clínic de Barcelona), Adina Soaita(Boehringer Ingelheim (United States)), Ivona Herichova(Boehringer Ingelheim (Austria)), Bojan Lalovic(Boehringer Ingelheim (United States)), Arthur Kaser(University of Cambridge), Chandrasena Pamulapati(Boehringer Ingelheim (United States)), Geert D’Haens(Amsterdam University Medical Centers), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Kyung‐Jo Kim(Asan Medical Center), Édouard Louis(Centre Hospitalier Universitaire de Liège), Sudha Visvanathan, David B. Hall(Boehringer Ingelheim (Germany)), Paul Scholl(Boehringer Ingelheim (United States)), Olivier Dewit
Cited by 449
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k